Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

537 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study.
Wilson S, Calocer F, Rollot F, Fauvernier M, Remontet L, Tron L, Vukusic S, Le Page E, Debouverie M, Ciron J, Ruet A, De Sèze J, Zephir H, Moreau T, Lebrun-Frénay C, Laplaud DA, Clavelou P, Labauge P, Berger E, Pelletier J, Heinzlef O, Thouvenot E, Camdessanché JP, Leray E, Dejardin O, Defer G. Wilson S, et al. Among authors: de seze j. Lancet Reg Health Eur. 2022 Nov 17;24:100542. doi: 10.1016/j.lanepe.2022.100542. eCollection 2023 Jan. Lancet Reg Health Eur. 2022. PMID: 36426377 Free PMC article.
Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.
Lebrun-Frénay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, Durand-Dubief F, Labauge P, Bensa C, Thouvenot E, Laplaud D, de Seze J, Ciron J, Bourre B, Cabre P, Casez O, Ruet A, Mathey G, Berger E, Moreau T, Al Khedr A, Derache N, Clavelou P, Guennoc AM, Créange A, Neau JP, Tourbah A, Camdessanché JP, Maarouf A, Callier C, Vermersch P, Kantarci O, Siva A, Azevedo C, Makhani N, Cohen M, Pelletier D, Okuda D, Vukusic S; RISC, SFSEP, and OFSEP Investigators. Lebrun-Frénay C, et al. Among authors: de seze j. JAMA Netw Open. 2021 Oct 1;4(10):e2128271. doi: 10.1001/jamanetworkopen.2021.28271. JAMA Netw Open. 2021. PMID: 34633424 Free PMC article.
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H; Italian MS Register; Observatoire Français de la Sclérose en Plaques (OFSEP); MSBase Study Group; Swedish MS Registry; Big MS Data Network. Lorscheider J, et al. Among authors: de seze j. J Neurol Neurosurg Psychiatry. 2024 Dec 6:jnnp-2024-334700. doi: 10.1136/jnnp-2024-334700. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39643429 Free article.
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Michel L, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. Lefort M, et al. Among authors: de seze j. Mult Scler. 2024 Dec 1:13524585241289276. doi: 10.1177/13524585241289276. Online ahead of print. Mult Scler. 2024. PMID: 39618051
Association between education level and disability progression in patients with multiple sclerosis in France.
Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Le Page E, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. Lefort M, et al. Among authors: de seze j. Mult Scler. 2024 Nov 30:13524585241289274. doi: 10.1177/13524585241289274. Online ahead of print. Mult Scler. 2024. PMID: 39614776
Assessment of the concomitant action of XBD173 and interferon β in a mouse model of multiple sclerosis using infrared marker bands.
Sirinukunwattana K, Klein C, Clarke PFA, Marcou G, Meyer L, Collongues N, de Sèze J, Hellwig P, Patte-Mensah C, El Khoury Y, Mensah-Nyagan AG. Sirinukunwattana K, et al. Among authors: de seze j. Spectrochim Acta A Mol Biomol Spectrosc. 2025 Feb 15;327:125390. doi: 10.1016/j.saa.2024.125390. Epub 2024 Nov 3. Spectrochim Acta A Mol Biomol Spectrosc. 2025. PMID: 39515236 Free article.
Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants.
Chalouni M, Loubet P, Lhomme E, Ninove L, Barrou B, Blay JY, Hourmant M, de Seze J, Laville M, Laviolle B, Lelièvre JD, Morel J, Quoc SN, Spano JP, Terrier B, Thiebaut A, Viallard JF, Vrtovsnik F, Circosta S, Barquin A, Gharib M, Tartour E, Parfait B, Thiébaut R, Meyer L, de Lamballerie X, Launay O, Wittkop L; ANRS0001S COV-POPART study group. Chalouni M, et al. Among authors: de seze j. BMC Infect Dis. 2024 Sep 27;24(1):1049. doi: 10.1186/s12879-024-09861-5. BMC Infect Dis. 2024. PMID: 39333909 Free PMC article.
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, Labauge P, De Sèze J, Vukusic S, Laplaud DA, Papeix C, Moreau T, Thouvenot E, Defer G, Lebrun-Frénay C, Ciron J, Berger E, Stankoff B, Clavelou P, Maillart E, Heinzlef O, Zéphir H, Ruet A, Casez O, Moulin S, Al-Khedr A, Bourre B, Pelletier J, Magy L, Neau JP, Camdessanché JP, Doghri I, Wahab A, Tchikviladzé M, Labeyrie C, Hankiewicz K, Le Page E, Michel L; as the OFSEP Investigators. Hay M, et al. Among authors: de seze j. Neurology. 2024 Oct 22;103(8):e209886. doi: 10.1212/WNL.0000000000209886. Epub 2024 Sep 25. Neurology. 2024. PMID: 39321406
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Allen JA, et al. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. Lancet Neurol. 2024. PMID: 39304241 Clinical Trial.
Teriflunomide, cognition and MRI: A longitudinal study.
Pfaff L, Mondino M, Loeb Q, Noblet V, Berthe C, Kremer L, Bigaut K, Collongues N, De Seze J. Pfaff L, et al. Among authors: de seze j. Mult Scler Relat Disord. 2024 Oct;90:105793. doi: 10.1016/j.msard.2024.105793. Epub 2024 Jul 31. Mult Scler Relat Disord. 2024. PMID: 39197351
537 results